Saturday 17 October 2026
Export IMCR’s income statement to Excel — free account
Immunocore Holdings PLC Sponsored ADR
IMCR Healthcare Biotechnology
Immunocore Holdings PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $400.0 million, up 29.0% from fiscal 2024. In the quarter to June 2026, revenue grew 18.3%, EPS grew 92.1%, free cash flow fell 40.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years.
29.40
0.08
−0.27%
Follow IMCR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.82 | 4.37 | 3.71 | 3.76 | |
P/FCF ratio |
612.02 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(410.95) | (53.51) | (111.09) | 101.61 | |
P/B ratio |
4.62 | 4.59 | 3.89 | 3.86 | |
Price to Tangible BV |
4.64 | 4.61 | 3.91 | 3.87 | |
EV/Sales |
3.63 | 3.31 | 2.73 | 2.74 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
172.62 | (123.66) | (45.23) | (33.77) | |
EV/FCF |
461.10 | (88.01) | (36.66) | (28.69) | |
Quick Ratio |
5.68 | 3.80 | 3.86 | 4.15 | |
Current Ratio |
6.00 | 4.04 | 4.18 | 4.47 | |
Net Debt/EBITDA |
78.42 | 24.98 | (54.84) | 246.70 | |
Debt/Assets |
35.61% | 36.83% | 36.72% | 35.22% | |
Debt/Equity |
0.99 | 1.03 | 1.00 | 0.94 | |
Asset Turnover |
0.35 | 0.39 | 0.39 | 0.39 | |
Operating CF/Net income |
25.18 | 1.09 | (1.06) | (19.71) | |
Capex/Depreciation |
(0.94) | (3.45) | (1.88) | (0.77) | |
Interest Coverage |
(2.36) | (6.45) | 2.39 | (0.98) | |
Research and Development Expense of Revenue |
68.06% | 75.44% | 57.29% | 63.79% | |
Selling, General and Administrative Expense of Revenue |
38.36% | 40.82% | 35.48% | 37.86% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
9.49% | 7.98% | 5.91% | 8.11% | |
Graham Net Nets |
0.17 | 0.18 | 0.21 | 0.22 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.58%) | (2.03%) | (1.80%) | (1.13%) | |
Free Cash Flow Yield |
0.16% | (0.86%) | (2.01%) | (2.54%) | |
Revenue per Share |
2.06 | 2.08 | 2.10 | 2.27 | |
Operating CF per Share |
(0.09) | (0.65) | (0.27) | 0.31 | |
Capex per Share |
(0.01) | (0.06) | (0.04) | (0.02) | |
Free Cash Flow per Share |
(0.10) | (0.71) | (0.31) | 0.30 | |
Cash per Share |
17.70 | 17.16 | 16.65 | 17.27 | |
Shareholders Equity per Share |
7.87 | 7.57 | 7.76 | 8.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.87 | 7.57 | 7.76 | 8.24 | |
Free Cash Flow |
(5.20) | (35.53) | (15.56) | 15.14 | |
Working Capital |
852.50 | 750.05 | 763.69 | 815.85 | |
Capital Expenditures |
(0.75) | (2.88) | (1.78) | (0.79) | |
Net Current Asset Value |
316.91 | 310.51 | 325.39 | 351.42 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.03 | 0.02 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
69.77 | 68.49 | 72.08 | 82.56 | |
Average Payables |
21.34 | 24.73 | 29.63 | 25.09 | |
Average Inventory |
5.09 | 6.09 | 7.53 | 6.62 | |
Average Assets |
1,093.57 | 1,038.39 | 1,050.05 | 1,100.90 | |
Average Common Equity |
387.20 | 370.87 | 386.08 | 404.14 |
Columns are period end dates